Cambrian

Cambrian Bio Named an Honoree of Fast Company's Next Big Things in Tech Award

Retrieved on: 
Tuesday, December 5, 2023
Research, Therapy, IND, Risk, Peyer, Telomere, Patient, Metabolism, Science, Health, Telos, Ageing, Infection, Cancer, Cell, Cellular senescence, Weight loss, Pharmaceutical industry, Amplifier, Cambrian

NEW YORK, Dec. 5, 2023 /PRNewswire/ -- Cambrian Bio, a New York-based clinical-stage drug development company, is among the honorees for Fast Company's Next Big Things in Tech 2023.

Key Points: 
  • NEW YORK, Dec. 5, 2023 /PRNewswire/ -- Cambrian Bio, a New York-based clinical-stage drug development company, is among the honorees for Fast Company's Next Big Things in Tech 2023.
  • The purpose of the award is to celebrate technological breakthroughs that are changing the way we live.
  • Each program is launched within Cambrian in collaboration with top drug developers and leading scientists.
  • "Thank you, Fast Company, for honoring our team's work as we create new technology to improve the health and performance of our cells and bodies," said James Peyer, CEO of Cambrian Bio.

Cambrian, a Leader in Wastewater Treatment, Water Reuse and Energy Recovery-As-A-Service, Receives Investment and $200 Million Growth Equity Commitment from Pennybacker

Retrieved on: 
Thursday, November 16, 2023
Keurig Dr Pepper, Infrastructure, WEPA, Food, Anheuser-Busch, Water, Discovery Land Company, Cambrian, Pennybacker, Boston

Based in Boston, and founded in 2011 by Chief Executive Officer Matthew Silver, Cambrian has developed innovative technology to address wastewater treatment problems.

Key Points: 
  • Based in Boston, and founded in 2011 by Chief Executive Officer Matthew Silver, Cambrian has developed innovative technology to address wastewater treatment problems.
  • The company has received accolades from the World Economic Forum as a technology pioneer and as a global circular economy leader.
  • "Across the U.S. and internationally the need for sustainable water treatment, water reuse, and clean energy, has never been greater," Matthew Silver, CEO of Cambrian said.
  • This investment is a great example of Pennybacker's differentiated infrastructure strategy and the value of the Pennybacker Platform."

Cambrium Secures €8 Million in Seed Funding to Commercialize New Class of Performance Molecules

Retrieved on: 
Tuesday, October 31, 2023
Marriage, Synthetic biology, Life, Biology, Machine learning, SNR, Automation, Fine chemical, Pharmaceutical industry, Cambrian, AI

With its new class of sustainable, high-performance molecules, Cambrium is transforming the paradigm of toxic petrochemicals and unethical animal ingredients currently found in a staggering majority of consumer products.

Key Points: 
  • With its new class of sustainable, high-performance molecules, Cambrium is transforming the paradigm of toxic petrochemicals and unethical animal ingredients currently found in a staggering majority of consumer products.
  • Bringing brands’ creative visions to reality, their molecules are enabling a new wave of essential products from skincare to apparel and footwear.
  • The funding will also accelerate the company’s product pipeline, with molecules for new applications and industries to be launched within the next two years.
  • “We founded Cambrium to accelerate past nature’s innovation cycle, for novel molecules that can quickly scale to material impact,” said Duffy.

Cambrium and Ginkgo Bioworks Complete Successful Collaboration on Data-Driven Cell Factory Engineering

Retrieved on: 
Tuesday, April 18, 2023
Cloud, DNA, State, Partnership, BMBF, Projection screen, Fermentation, Cell, Federal Ministry of Budget and National Planning (Nigeria), Ginkgo Bioworks, Ginkgo, Machine learning, Algorithm, NYSE, Education, Dietary supplement, Cambrian, Research

BERLIN and BOSTON, April 18, 2023 /PRNewswire/ -- Cambrium, a leading German start-up focused on the application of generative AI to protein design and synthesis, and Ginkgo Bioworks (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced the successful completion of their collaboration.

Key Points: 
  • BERLIN and BOSTON, April 18, 2023 /PRNewswire/ -- Cambrium, a leading German start-up focused on the application of generative AI to protein design and synthesis, and Ginkgo Bioworks (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced the successful completion of their collaboration.
  • Through the partnership, Cambrium and Ginkgo combined their capabilities to enable the rapid and cost-effective design of high performing, industrially relevant microbes for protein production.
  • Almost 2 years ago, Cambrium and FGen, a subsidiary of Ginkgo now known as Ginkgo's Encapsulation and Screening team, announced a partnership to push the boundaries of data-driven metabolic engineering.
  • Through the collaboration, the teams were able to identify non-obvious engineering targets to significantly improve strain performance.

Cambrium Launches NovaColl™: First Micro-Molecular & Skin-Identical Collagen Ingredient for Personal Care Industry

Retrieved on: 
Thursday, March 23, 2023
Collagen, Animal, Skin, Water, Tanning (leather), Dietary supplement, Cambrian

It is the first micro-molecular & 100% skin-identical collagen specifically designed for premium personal care formulations.

Key Points: 
  • It is the first micro-molecular & 100% skin-identical collagen specifically designed for premium personal care formulations.
  • Owing to its structure and small molecular size, NovaColl™ is able to create powerful collagen benefits across skin layers.
  • They identified NovaColl™, a highly bioactive region of collagen I, the most prevalent collagen type in our human skin.
  • Rather than extracting collagen from animals, Cambrium uses yeast cells to grow their micro-molecular collagen in a cruelty-free and sustainable fermentation process, minimizing energy, land, and water use.

Cambrian Bio launches Amplifier Therapeutics to develop clinical-stage AMPK activator

Retrieved on: 
Tuesday, March 14, 2023
Kidney, Blood, Ageing, Amplifier, Dicarboxylic acid, Fasting, Patient, Doctor of Philosophy, Exercise, Cancer, Therapy, Safety, Research, EVP, ATP, AstraZeneca, AMPK, Pharmaceutical industry, Cambrian, MD

NEW YORK, March 14, 2023 /PRNewswire/ -- Cambrian Bio, a clinical-stage biotechnology company focused on treating and preventing chronic diseases of aging, today announced the launch of its new pipeline company, Amplifier Therapeutics. The organization will develop ATX-304, a pan-AMPK (AMP-activated protein kinase) activator. Amplifier has acquired Betagenon AB, a Swedish biopharmaceutical company, which has discovered novel AMPK activators and will continue development as a part of the Amplifier team.

Key Points: 
  • Amplifier has acquired Betagenon AB , a Swedish biopharmaceutical company, which has discovered novel AMPK activators and will continue development as a part of the Amplifier team.
  • "AMPK is one of the most sought-after drug targets in aging research," said James Peyer, PhD, CEO of Cambrian Bio.
  • "Amplifier and Cambrian are thrilled to work with the former Betagenon team and investors to develop a first-of-its-kind AMPK activator.
  • Cambrian Bio and Amplifier Therapeutics will initiate a Proof of Mechanism Phase 1b study later this year.

Cambrian Bio launches Amplifier Therapeutics to develop clinical-stage AMPK activator

Retrieved on: 
Tuesday, March 14, 2023
Kidney, Blood, Ageing, Amplifier, Dicarboxylic acid, Fasting, Patient, Doctor of Philosophy, Exercise, Cancer, Therapy, Safety, Research, EVP, ATP, AstraZeneca, AMPK, Pharmaceutical industry, Cambrian, MD

NEW YORK, March 14, 2023 /PRNewswire/ -- Cambrian Bio, a clinical-stage biotechnology company focused on treating and preventing chronic diseases of aging, today announced the launch of its new pipeline company, Amplifier Therapeutics. The organization will develop ATX-304, a pan-AMPK (AMP-activated protein kinase) activator. Amplifier has acquired Betagenon AB, a Swedish biopharmaceutical company, which has discovered novel AMPK activators and will continue development as a part of the Amplifier team.

Key Points: 
  • Amplifier has acquired Betagenon AB , a Swedish biopharmaceutical company, which has discovered novel AMPK activators and will continue development as a part of the Amplifier team.
  • "AMPK is one of the most sought-after drug targets in aging research," said James Peyer, PhD, CEO of Cambrian Bio.
  • "Amplifier and Cambrian are thrilled to work with the former Betagenon team and investors to develop a first-of-its-kind AMPK activator.
  • Cambrian Bio and Amplifier Therapeutics will initiate a Proof of Mechanism Phase 1b study later this year.

Cambrian Biopharma CEO James Peyer Named 2022 "BioTech Company CEO of the Year" By BioTech Breakthrough

Retrieved on: 
Friday, November 4, 2022
People, Leadership, Company, Science, Therapy, Founder, Sutro Biopharma, Multimedia, Yissum Research Development Company of the Hebrew University, Biotechnology, Peyer, Solution, Woman, Ageing, Safety, Tornado, Quality of life, CEO, Longevity, Geroprotector, Health, Drug development, Disco, Year, Photoionization, Efficiency, Fine chemical, Pharmaceutical industry, Cambrian, Genomics

NEW YORK , Nov. 4, 2022 /PRNewswire/ -- Cambrian BioPharma, a multi-asset longevity biotech, today announced that its CEO, James Peyer, has been selected as "BioTech Company CEO of the Year" in the second annual BioTech Breakthrough Awards, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.

Key Points: 
  • James Peyer, Ph.D., is CEO and Founder of Cambrian Biopharma, which is bridging the gap between academic discovery and drug development, under their Distributed Development Company (or DisCo) model.
  • Since 2019, Peyer's Cambrian has grown from three drugs more than a dozen therapeutics that are currently in development.
  • "Thank you so much to BioTech Breakthrough for honoring me and the work of my entire team in this way.
  • Congratulations to James Peyer on winning 'BioTech Company CEO of the Year' for 2022."

Cambrian BioPharma Appoints Ruth Thieroff-Ekerdt as Executive Vice President of Clinical Development

Retrieved on: 
Wednesday, September 21, 2022
Photoionization, Therapy, Health, Organon, Ageing, Twitter, Longevity, MD, Free University of Berlin, Coronavirus Scientific Advisory Board (Turkey), Publication, LinkedIn, Bayer, Acting, Cros, Patient, Physician, CEO, Quality of life, Dr. med. Sommer II, Degenerative disease, R, Multimedia, KOL, Drug, View, Pharmaceutical industry, Cambrian, Pharmacology, Ruth, EU

NEW YORK, Sept. 21, 2022 /PRNewswire/ -- Cambrian BioPharma , a multi-asset longevity biotech, today announces the appointment of Ruth Thieroff-Ekerdt, M.D., as Executive Vice President of Clinical Development.

Key Points: 
  • NEW YORK, Sept. 21, 2022 /PRNewswire/ -- Cambrian BioPharma , a multi-asset longevity biotech, today announces the appointment of Ruth Thieroff-Ekerdt, M.D., as Executive Vice President of Clinical Development.
  • "Adding Ruth to the Cambrian team is an important step towards ensuring our work to increase healthspan while creating life-changing medicines for patients suffering from diseases today," said James Peyer, CEO, Cambrian BioPharma.
  • "Her background and vast knowledge of clinical development will allow Cambrian to thoughtfully advance our wide array of programs into human trials."
  • In her role, Dr. Thieroff-Ekerdt will be responsible for a broad range of development activities including the continuation and creation of clinical development and strategy.

Cambrian Ventures launches with a $20 million fund backed by top fintech entrepreneurs

Retrieved on: 
Tuesday, July 26, 2022
Knowledge, Investment, Industry, SAN, LendUp, Software, Kabbage, Betterment, General partnership, Science and technology in Asia, Plaid, Andreessen Horowitz, SoFi, Dwight Schrute, Blend, Growth, American Express, Bank, Cryptocurrency, NerdWallet, Jeeves, Cambrian

SAN FRANCISCO, July 26, 2022 /PRNewswire-PRWeb/ -- Cambrian Ventures, a new early-stage venture capital firm led by former Andreessen Horowitz partner Rex Salisbury, today launched its inaugural $20 million fintech-focused fund investing at the angel, pre-seed and seed stage.

Key Points: 
  • Among the fund's investors are some of the most influential entrepreneurs and operators in the fintech sector.
  • "The fund aims to leverage the entrepreneurial experience, subject matter expertise, operational expertise, and industry insights within the Cambrian community to support the next generation of fintech entrepreneurs."
  • "We are delighted to see how he and Cambrian will continue to support the fintech ecosystem with the launch of this fund."
  • About: Cambrian Ventures is an early-stage venture capital firm supporting entrepreneurs in fintech.